Pharmanovia appoints Nivedita Valentine as VP of Product Innovation


Share post:

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation.

Ms Valentine will oversee the company’s product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships.

Ms Valentine currently holds  positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook.

Pharmanovia CEO Dr James Burt commented: “Digitalization and utilizing the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita’s appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

“I am delighted to welcome Nivedita to Pharmanovia as we continue the next phase of our strategic growth journey.”

Backed by more than fifteen years of leadership experience, Ms Valentine brings deep market knowledge and technical expertise to Pharmanovia’s product innovation division. Previously she has held global senior management positions at Accord Healthcare and Glenmark Pharmaceuticals.

Commenting on her new role, Ms Valentine said: “Pharmanovia is at an incredibly exciting point within its growth journey, rapidly establishing its position as a leader in life cycle management with a strong, innovative pipeline.

“I’m excited to take on this role within such a committed, patient-centered organization with an incredibly talented, like-minded team who constantly seek to identify new ways to enhance the lives of the patients.”



Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...